Latest Articles
FABP7 Boosts Endometrial Cancer Cell Mobility and Stemness - Bioengineer.org
FABP7 Boosts Endometrial Cancer Cell Mobility and Stemness Bioengineer.org
Published: Dec. 16, 2025, 10:18 p.m.
Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid - Bioengineer.org
Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid Bioengineer.org
Published: Dec. 16, 2025, 9:38 p.m.
Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid - BIOENGINEER.ORG
Metabolic Syndrome Fuels Endometrial Cancer via Oleic Acid BIOENGINEER.ORG
Published: Dec. 16, 2025, 9:38 p.m.
Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update - Cureus
Mismatch Repair Deficiency Profiling and Its Impact on Management and Prognosis in Endometrial Cancer Patients: A Comprehensive Update Cureus
Published: Dec. 16, 2025, 12:29 p.m.
Endometrial cancer treatment enters a paradigm shift: expert - koreabiomed.com
Endometrial cancer treatment enters a paradigm shift: expert koreabiomed.com
Published: Dec. 16, 2025, 8:01 a.m.
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer - Cancer Nursing Today
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Treatment for Endometrial Cancer Cancer Nursing Today
Published: Dec. 15, 2025, 8:24 p.m.
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer - Cancer Nursing Today
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer Cancer Nursing Today
Published: Dec. 15, 2025, 8:24 p.m.
Endometrial Cancer Remission Rate: What Patients Need to Know in 2025 - Oncodaily
Endometrial Cancer Remission Rate: What Patients Need to Know in 2025 Oncodaily
Published: Dec. 7, 2025, 4:41 p.m.
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling - Nature
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling Nature
Published: Dec. 6, 2025, 7:16 p.m.
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence - OncLive
Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence OncLive
Published: Dec. 5, 2025, 1 p.m.
Link copied to clipboard!